The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...

CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Click here ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

A synthetic form of the active ingredient in magic mushrooms has cleared an early-phase trial. The drug, Compass Pathways’ COMP360, came through the placebo-controlled phase 1 without setting off any ...

William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and ...

Compass Pathways has filed paperwork for a Nasdaq IPO that will tee it up to take psilocybin therapy COMP360 through midphase development. Compass is developing psilocybin, the active ingredient in ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara ®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that the entire ...